Primary Peritoneal Carcinoma Completed Phase 2 Trials for Ramucirumab (DB05578)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00721162Study of Ramucirumab in Ovarian CancerTreatment